Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvanted Influenza Vaccine in Nursing Homes
NCT02882100Phase 4Completed
- Sponsor
- Insight Therapeutics
- Start
- Apr 2016
- Primary completion
- Oct 2018
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adjuvanted trivalent subunit influenza vaccine in influenza (2 arms), sponsored by Insight Therapeutics. Primary endpoints: Hospitalization for a respiratory-related Illness at 1 year and Hospitalization for all causes at 1 year. Started Apr 2016; status: completed.
02
Drugs
adjuvanted trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02882100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882100.